Mainz Biomed, GANZIMMUN launch enhanced ColoAlert CRC screening test

Mainz Biomed (MYNZ) announced that its partner, GANZIMMUN Diagnostics, has officially launched the enhanced ColoAlert colorectal cancer screening test. Starting this January, patients across Germany can access this new version of the Company’s screening test, in time for Colorectal Cancer Awareness Month in March. First introduced by Mainz Biomed in mid-2024, the enhanced ColoAlert features advancements, including a proprietary DNA stabilizing buffer, to deliver accurate results even with varying sample volumes.